Stay updated on Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.

Latest updates to the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedA sitewide NIH banner announces a transition update, including the use of “Super Intelligence” in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check21 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2 while the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check48 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the expected study record, indicating an access restriction or server issue that prevents loading the study details at this time.SummaryDifference19%

- Check69 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a minor update to the page's version metadata. The study details remain unchanged.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.